Coherus BioSciences to Report First Quarter 2017 Financial Results on May 8th

Monday, April 24, 2017 1:00 PM UTC

REDWOOD CITY, Calif., April 24, 2017 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its first quarter 2017 financial results will be released after market close on Monday, May 8, 2017. At 4:30 p.m. EDT, Coherus’ management will host a conference call to discuss the financial results and provide a general business update.

After releasing first quarter 2017 financial results, we will post them on the Coherus BioSciences website at http://investors.coherus.com.

Conference Call Information
When: Monday, May 8, 2017 at 4:30 p.m. EDT
Dial-in: (844) 452-6826 (toll free) or (765) 507-2587 (International)
Conference ID: 8313325
Webcast: http://investors.coherus.com
Please join the conference call at least 10 minutes early to register. The webcast will be archived on the Coherus website.

About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.

CONTACT:
Patrick O’Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
+1 (650) 649-3527

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Coherus BioSciences to Report First Quarter 2017 Financial Results on May 8th

Editor's Picks

Welcome to EconoTimes